ATAS-EMIT Activates the 5-HT/AC/cAMP Pathway to Ameliorate Insomnia in PCPA Insomniac Rats

ATAS-EMIT激活5-HT/AC/cAMP通路以改善PCPA失眠大鼠的失眠症状

阅读:1

Abstract

BACKGROUND: Insomnia may lead to or be co-morbid with mental disorders. However, available treatments have significant side effects. Time-acupoints-space acupuncture, eight methods of intelligent turtle (ATAS-EMIT), as a low-hazard insomnia treatment, has been focused on. METHODS: Thirty-six rats were randomly divided into 4 groups: normal (Control), insomnia (Model), ATAS-EMIT treatment (Treatment), and sham acupuncture treatment (Sham). Behavioral experiments were used to assess the treatment of ATAS-EMIT for insomnia. ELISA, Western blot, and immunofluorescence staining were used to detect the expression of 5-HT, AC, cAMP, 5HT(1A) receptor (5HT(1AR)), and 5HT(2A) receptor (5HT(2AR)) in rat hippocampus. Transcriptome sequencing was used to explore more therapeutic mechanisms. RESULTS: ATAS-EMIT treatment significantly reduced anxiety-like behaviors and activities in PCPA insomniac rats in the open field test. Additionally, ATAS-EMIT significantly shortened the sleep latency period in insomnia-prone rats while prolonging both sleep duration and hanging rest time. These behavioral studies suggest that ATAS-EMIT is a treatment for insomnia. The insomnia-related indicators showed that ATAS-EMIT significantly activated the 5-HT/AC/cAMP pathway, promoted the expression of the 5HT(1AR), and inhibited the expression of the 5HT(2AR) for therapeutic purposes. Subsequent transcriptome sequencing revealed that ATAS-EMIT-treated DEGs were enriched for multiple insomnia-related functions such as phototransduction, stimulus-response, and tryptophan metabolism. Six key genes, Cngb1, Cabp4, Sag, Tyr, Trpm1, and Adipoq, were screened and validated. CONCLUSION: ATAS-EMIT significantly improved insomnia symptoms in PCPA insomniac rats, and activation of the 5-HT/AC/cAMP pathway was involved. Various mechanisms, such as phototransduction, tryptophan metabolism, and reduction of stimulation, contributed to the therapeutic effects of ATAS-EMIT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。